ArticleMedicine2026
Network meta-analysis of intrathyroidal injection of combined dexamethasone with lidocaine for subacute thyroiditis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrathyroidal injection of dexamethasone (Dex) alone (monotherapy) or combined Dex with lidocaine (combination therapy) has been used for treating subacute thyroiditis (SAT). We performed this study to simultaneously determine whether intrathyroidal injection of Dex was better than oral prednisone and whether combination therapy was superior to monotherapy.
methodsWe identified studies from PubMed, Embase, Cochrane library, China National Knowledge Infrastructure (CNKI), and Wanfang databases through December 31, 2021. Clinical efficacy, recurrence rate, adverse reactions, and remission time of clinical symptoms including fever, pain of thyroid and thyroid enlargement were assessed. The surface under the cumulative ranking curve (SUCRA) was estimated to determine the rank probabilities, and radar plot was to determine the optimal protocol. STATA 14 was utilized for data analysis.
resultsTwenty-three studies were included. Results revealed that, compared with oral prednisone, intrathyroidal injection significantly increased clinical efficacy and shortened remission time of clinical symptoms. However, no difference between the 2 protocols of intrathyroidal injection of prednisone was detected. Radar plot suggested that monotherapy might be the optimal protocol for recurrence rate (79.9%), remission time of fever (83.6%) and pain of thyroid (92.5%), and adverse reactions (87.1%); however, combination therapy for clinical efficacy (80.0%) and remission time of thyroid enlargement (93.7%).
conclusionIntrathyroidal injection of Dex is better than oral prednisone for treating SAT, and monotherapy should be recommended over combination therapy because combination therapy do not produce additional therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.